Updates are available Correction dated 2023-03-04

Article History

Accepted: 2 October 2022

First Online: 4 November 2022

Change Date: 4 March 2023

Change Type: Correction

Change Details: A Correction to this paper has been published:

Change Details: https://doi.org/10.1007/s40291-023-00643-4

Declarations

:

: This research was wholly funded by Alexion, AstraZeneca Rare Disease, Boston, MA, USA, and did not receive any specific grant from funding agencies in the public, commercial or not-for-profit sectors.

: As described in the original study publication.

: As described in the original study publication.

: As described in the original study publication.

: All authors are employees and stockholders of Alexion, AstraZeneca Rare Disease, Boston, MA, USA.

: All authors met ICMJE authorship criteria, contributed to the study conception and design, material preparation, data collection, critical review of the draft manuscript and approval of the final manuscript.

: Alexion will consider requests for disclosure of clinical study participant-level data provided that participant privacy is assured through methods like data de-identification, pseudonymization, or anonymization (as required by applicable law), and if such disclosure was included in the relevant study informed consent form or similar documentation. Qualified academic investigators may request participant-level, deidentified clinical data and supporting documents (statistical analysis plan and protocol) pertaining to Alexion-sponsored studies. Further details regarding data availability, and instructions for requesting information are available in the Alexion Clinical Trials Disclosure and Transparency Policy at .

: Not applicable.